Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

Molecular profiling of Spitz nevi identified by digital RNA counting.

Hillen LM, Geybels MS, Rennspiess D, Spassova I, Ritter C, Becker JC, Garmyn M, Zur Hausen A, Van den Oord J, Winnepenninckx V.

Melanoma Res. 2018 Aug 7. doi: 10.1097/CMR.0000000000000495. [Epub ahead of print]

PMID:
30095598
2.

Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma.

Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Odum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC.

Clin Cancer Res. 2018 Jul 30. pii: clincanres.1184.2018. doi: 10.1158/1078-0432.CCR-18-1184. [Epub ahead of print]

PMID:
30061360
3.

Relational mobility predicts social behaviors in 39 countries and is tied to historical farming and threat.

Thomson R, Yuki M, Talhelm T, Schug J, Kito M, Ayanian AH, Becker JC, Becker M, Chiu CY, Choi HS, Ferreira CM, Fülöp M, Gul P, Houghton-Illera AM, Joasoo M, Jong J, Kavanagh CM, Khutkyy D, Manzi C, Marcinkowska UM, Milfont TL, Neto F, von Oertzen T, Pliskin R, San Martin A, Singh P, Visserman ML.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):7521-7526. doi: 10.1073/pnas.1713191115. Epub 2018 Jun 29.

4.

SATB1 in Malignant T Cells.

Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N.

J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8.

PMID:
29751003
5.

Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression.

Maier IL, Becker JC, Leyhe JR, Schnieder M, Behme D, Psychogios MN, Liman J.

PLoS One. 2018 Apr 25;13(4):e0196174. doi: 10.1371/journal.pone.0196174. eCollection 2018.

6.

Checkpoint-Inhibitor nun auch zur Therapie des metastasierten Merkelzellkarzinoms zugelassen.

Grabbe S, Terheyden P, Becker JC.

J Dtsch Dermatol Ges. 2018 Mar;16(3):394-395. doi: 10.1111/ddg.13432. No abstract available.

PMID:
29537164
7.

The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment.

Stang A, Becker JC, Nghiem P, Ferlay J.

Eur J Cancer. 2018 May;94:47-60. doi: 10.1016/j.ejca.2018.02.003. Epub 2018 Mar 20.

8.

A short-term in vivo model for Merkel Cell Carcinoma.

Bhat VK, Krump C, Bernhart E, Becker JC, Sattler W, Ghaffari-Tabrizi-Wizsy N.

Exp Dermatol. 2018 Jun;27(6):684-687. doi: 10.1111/exd.13529. Epub 2018 Mar 26.

PMID:
29509994
9.

Body Covering and Body Image: A Comparison of Veiled and Unveiled Muslim Women, Christian Women, and Atheist Women Regarding Body Checking, Body Dissatisfaction, and Eating Disorder Symptoms.

Wilhelm L, Hartmann AS, Becker JC, Kişi M, Waldorf M, Vocks S.

J Relig Health. 2018 Feb 21. doi: 10.1007/s10943-018-0585-3. [Epub ahead of print]

PMID:
29468534
10.

S2k-Leitlinie: HPV-assoziierte Läsionen der äußeren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung).

Gross GE, Werner RN, Becker JC, Brockmeyer NH, Esser S, Hampl M, Hommel S, Jongen J, Mestel DS, Meyer T, Petry KU, Plettenberg A, Püschel K, Schneede P, Schöfer H, Sotlar K, Weyandt G, Wieland U, Wiese-Posselt M, Nast A.

J Dtsch Dermatol Ges. 2018 Feb;16(2):242-256. doi: 10.1111/ddg.13441_g. No abstract available.

PMID:
29418090
11.

S2k guideline: HPV-associated lesions of the external genital region and the anus - anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version).

Gross GE, Werner RN, Becker JC, Brockmeyer NH, Esser S, Hampl M, Hommel S, Jongen J, Mestel DS, Meyer T, Petry KU, Plettenberg A, Püschel K, Schneede P, Schöfer H, Sotlar K, Weyandt G, Wieland U, Wiese-Posselt M, Nast A.

J Dtsch Dermatol Ges. 2018 Feb;16(2):242-255. doi: 10.1111/ddg.13441. No abstract available.

PMID:
29418083
12.

Positive stereotypes, negative outcomes: Reminders of the positive components of complementary gender stereotypes impair performance in counter-stereotypical tasks.

Kahalon R, Shnabel N, Becker JC.

Br J Soc Psychol. 2018 Apr;57(2):482-502. doi: 10.1111/bjso.12240. Epub 2018 Jan 26.

PMID:
29377186
13.

S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2018 Jan;16(1):112-123. doi: 10.1111/ddg.13401_g. No abstract available.

PMID:
29314698
14.

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2018 Jan;16(1):112-122. doi: 10.1111/ddg.13401. Epub 2017 Dec 27. No abstract available.

PMID:
29280595
15.

S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1266-1273. doi: 10.1111/ddg.13372_g. No abstract available.

PMID:
29228489
16.

Subcutaneous local anesthetic infusion could eliminate use of epidural analgesia after the Nuss procedure.

Kabagambe SK, Goodman LF, Chen YJ, Keller BA, Becker JC, Raff GW, Stark RA, Stephenson JT, Rahm A, Farmer DL, Hirose S.

Pain Manag. 2018 Jan;8(1):9-13. doi: 10.2217/pmt-2017-0042. Epub 2017 Dec 6.

PMID:
29210330
17.

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1266-1273. doi: 10.1111/ddg.13372. Epub 2017 Nov 28. No abstract available.

PMID:
29193659
18.

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Becker JC, Stang A, Hausen AZ, Fischer N, DeCaprio JA, Tothill RW, Lyngaa R, Hansen UK, Ritter C, Nghiem P, Bichakjian CK, Ugurel S, Schrama D.

Cancer Immunol Immunother. 2018 Mar;67(3):341-351. doi: 10.1007/s00262-017-2099-3. Epub 2017 Nov 30. Review.

19.

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.

Becker JC, Lorenz E, Ugurel S, Eigentler TK, Kiecker F, Pföhler C, Kellner I, Meier F, Kähler K, Mohr P, Berking C, Haas G, Helwig C, Oksen D, Schadendorf D, Mahnke L, Bharmal M.

Oncotarget. 2017 Jul 13;8(45):79731-79741. doi: 10.18632/oncotarget.19218. eCollection 2017 Oct 3.

20.

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.

Ugurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderkötter C, Stein A, Fluck M, Kaatz M, Trefzer U, Kähler K, Stadler R, Berking C, Höller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC.

Oncotarget. 2017 Jun 27;8(44):76029-76043. doi: 10.18632/oncotarget.18635. eCollection 2017 Sep 29.

21.

Merkel cell carcinoma.

Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P.

Nat Rev Dis Primers. 2017 Oct 26;3:17077. doi: 10.1038/nrdp.2017.77. Review.

22.

Facilitators of high-quality teaching in medical school: findings from a nation-wide survey among clinical teachers.

Schiekirka-Schwake S, Anders S, von Steinbüchel N, Becker JC, Raupach T.

BMC Med Educ. 2017 Sep 29;17(1):178. doi: 10.1186/s12909-017-1000-6.

23.

Intergroup Contact and Social Change: Implications of Negative and Positive Contact for Collective Action in Advantaged and Disadvantaged Groups.

Reimer NK, Becker JC, Benz A, Christ O, Dhont K, Klocke U, Neji S, Rychlowska M, Schmid K, Hewstone M.

Pers Soc Psychol Bull. 2017 Jan;43(1):121-136. doi: 10.1177/0146167216676478.

PMID:
28903647
24.

Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim Melanom.

Cosgarea I, Ritter C, Becker JC, Schadendorf D, Ugurel S.

J Dtsch Dermatol Ges. 2017 Sep;15(9):887-894. doi: 10.1111/ddg.13321_g. Review.

PMID:
28872247
25.

Update on the clinical use of kinase inhibitors in melanoma.

Cosgarea I, Ritter C, Becker JC, Schadendorf D, Ugurel S.

J Dtsch Dermatol Ges. 2017 Sep;15(9):887-893. doi: 10.1111/ddg.13321. Review.

PMID:
28872233
26.

Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S.

Leuk Lymphoma. 2018 Apr;59(4):880-887. doi: 10.1080/10428194.2017.1361022. Epub 2017 Aug 30.

PMID:
28853310
27.

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.

Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. No abstract available.

PMID:
28735071
28.

Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma.

Sauer CM, Haugg AM, Chteinberg E, Rennspiess D, Winnepenninckx V, Speel EJ, Becker JC, Kurz AK, Zur Hausen A.

Crit Rev Oncol Hematol. 2017 Aug;116:99-105. doi: 10.1016/j.critrevonc.2017.05.009. Epub 2017 Jun 3. Review.

29.

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.

Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC.

Sci Rep. 2017 May 23;7(1):2290. doi: 10.1038/s41598-017-02608-0.

30.

MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.

Improta G, Ritter C, Pettinato A, Vasta V, Schrama D, Fraggetta F, Becker JC.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1489-1497. doi: 10.1007/s00432-017-2413-7. Epub 2017 Apr 12.

PMID:
28405827
31.

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC.

Future Oncol. 2017 Jun;13(14):1263-1279. doi: 10.2217/fon-2017-0072. Epub 2017 Mar 28. Review.

32.

Non-reproducible sequence artifacts in FFPE tissue: an experience report.

Ofner R, Ritter C, Ugurel S, Cerroni L, Stiller M, Bogenrieder T, Solca F, Schrama D, Becker JC.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1199-1207. doi: 10.1007/s00432-017-2399-1. Epub 2017 Mar 17.

PMID:
28314930
33.

New developments in the biology and the treatment of metastatic Merkel cell carcinoma.

Terheyden P, Becker JC.

Curr Opin Oncol. 2017 Mar 9. doi: 10.1097/CCO.0000000000000363. [Epub ahead of print]

PMID:
28282342
34.

Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?

Ugurel S, Becker JC.

J Invest Dermatol. 2017 Feb;137(2):277-279. doi: 10.1016/j.jid.2016.10.027.

35.

T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.

Schrama D, Ritter C, Becker JC.

Semin Immunopathol. 2017 Apr;39(3):255-268. doi: 10.1007/s00281-016-0614-9. Epub 2017 Jan 10. Review.

PMID:
28074285
36.

Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.

Ofner R, Ritter C, Heidenreich B, Kumar R, Ugurel S, Schrama D, Becker JC.

J Cancer Res Clin Oncol. 2017 Apr;143(4):613-617. doi: 10.1007/s00432-016-2322-1. Epub 2016 Dec 18.

PMID:
27990595
37.

Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs.

Schadendorf D, Lebbé C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, Becker JC.

Eur J Cancer. 2017 Jan;71:53-69. doi: 10.1016/j.ejca.2016.10.022. Epub 2016 Dec 14. Review.

38.

Left-sided laterality of Merkel cell carcinoma in a German population: more than just sun exposure.

Gambichler T, Wieland U, Silling S, Dreißigacker M, Schaller J, Schulze HJ, Oellig F, Kreuter A, Stücker M, Bechara FG, Stockfleth E, Becker JC.

J Cancer Res Clin Oncol. 2017 Feb;143(2):347-350. doi: 10.1007/s00432-016-2293-2. Epub 2016 Oct 24.

PMID:
27778198
39.

Intercostal nerve cryoablation versus thoracic epidural catheters for postoperative analgesia following pectus excavatum repair: Preliminary outcomes in twenty-six cryoablation patients.

Keller BA, Kabagambe SK, Becker JC, Chen YJ, Goodman LF, Clark-Wronski JM, Furukawa K, Stark RA, Rahm AL, Hirose S, Raff GW.

J Pediatr Surg. 2016 Dec;51(12):2033-2038. doi: 10.1016/j.jpedsurg.2016.09.034. Epub 2016 Sep 28.

PMID:
27745867
40.

Prognostic relevance of high atonal homolog-1 expression in Merkel cell carcinoma.

Gambichler T, Mohtezebsade S, Wieland U, Silling S, Höh AK, Dreißigacker M, Schaller J, Schulze HJ, Oellig F, Kreuter A, Stockfleth E, Stücker M, Bechara FG, Becker JC.

J Cancer Res Clin Oncol. 2017 Jan;143(1):43-49. doi: 10.1007/s00432-016-2257-6. Epub 2016 Sep 13.

PMID:
27624714
41.

A national reconnaissance of trace organic compounds (TOCs) in United States lotic ecosystems.

Bernot MJ, Becker JC, Doll J, Lauer TE.

Sci Total Environ. 2016 Dec 1;572:422-433. doi: 10.1016/j.scitotenv.2016.08.060. Epub 2016 Aug 17.

PMID:
27543946
42.

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab.

Williams JH, Hutmacher MM, Zierhut ML, Becker JC, Gumbiner B, Spencer-Green G, Melia LA, Liao KH, Suster M, Yin D, Li R, Meng X.

Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579. doi: 10.1111/bcp.13094. Epub 2016 Sep 22.

43.

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A.

Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3.

44.

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.

Roesch A, Paschen A, Landsberg J, Helfrich I, Becker JC, Schadendorf D.

Eur J Cancer. 2016 May;59:109-112. doi: 10.1016/j.ejca.2016.02.023. Epub 2016 Mar 26.

PMID:
27023049
45.

A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.

Cohen S, Emery P, Greenwald M, Yin D, Becker JC, Melia LA, Li R, Gumbiner B, Thomas D, Spencer-Green G, Meng X.

Br J Clin Pharmacol. 2016 Jul;82(1):129-38. doi: 10.1111/bcp.12916. Epub 2016 Apr 29.

46.

Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma.

Ritter C, Fan K, Paulson KG, Nghiem P, Schrama D, Becker JC.

Sci Rep. 2016 Feb 23;6:21678. doi: 10.1038/srep21678.

47.

Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, Nielsen J, Gehl J, Pedersen BK, Thor Straten P, Hojman P.

Cell Metab. 2016 Mar 8;23(3):554-62. doi: 10.1016/j.cmet.2016.01.011. Epub 2016 Feb 16.

48.

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.

Willmes C, Kumar R, Becker JC, Fried I, Rachakonda PS, Poppe LM, Hesbacher S, Schadendorf D, Sucker A, Schrama D, Ugurel S.

Oncotarget. 2016 Mar 1;7(9):10117-32. doi: 10.18632/oncotarget.6956.

49.

Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types.

Richtig E, Asslaber M, Partl R, Avian A, Berghold A, Kapp K, Preusser M, Becker JC, Curiel-Lewandrowski C.

Clin Neuropathol. 2016 Mar-Apr;35(2):89-92. doi: 10.5414/NP300903. No abstract available.

PMID:
26636558
50.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

Supplemental Content

Loading ...
Support Center